iCentric

iCentric Therapeutics is a UK-based biotechnology company focused on the discovery and development of highly selective small molecule inhibitors for the treatment of cancer. A spin-out from the University of Nottingham, the company leverages the research of Professor Shudong Wang, a leading expert in medicinal chemistry and kinase inhibition. iCentric's pipeline is centered on targeting cyclin-dependent kinases (CDKs), particularly CDK9 and CDK2, which are critical drivers of cell proliferation and survival in various malignancies. Their lead candidates are designed to offer superior potency and selectivity compared to earlier generations of CDK inhibitors, aiming to minimize off-target effects. The company is primarily targeting hematological cancers such as acute myeloid leukemia (AML) and various advanced solid tumors.